
V-domain
Ligand binding
2 N-glycosylation sites
N100
Ligand binding
interface
N160
N113
N230
C-domain
3 N-glycosylation sites
N209

FIG. 1

Features:

```
Query              DPNFWLQVQESVTVQEGLCVLVPCTFFHPIPYYDKNSPVHGYWFREGAIISRD  70
                   DP   L+VQESVTVQEGLCVLVPCTFFHP+PY+ +NSPVHGYWFREGAI+S D
Sbjct              DPRVRLEVQESVTVQEGLCVLVPCTFFHPVPYHTRNSPVHGYWFREGAIVSLD  89

Query  71    SPVATNKLDQEVQEETQGRFRLLGDPSRNNCSLSIVDARRRDNGSYFFRMERGSTKYSYK  130
             SPVATNKLDQEVQEETQGRFRLLGDPSRNNCSLSIVDARRRDNGSYFFRME+GSTKYSYK
Sbjct  90    SPVATNKLDQEVQEETQGRFRLLGDPSRNNCSLSIVDARRRDNGSYFFRMEKGSTKYSYK  149

Query  131   SPQLSVHVTDLTHRPKILIPGTLEPGHSKNLTCSVSWACEQGTPPIFSWLSAAPTSLGPR  190
             S QLSVHVTDLTHRP+ILIPG L+P HSKNLTCSV WACEQGTPPIFSW+SAAPTSLG R
Sbjct  150   STQLSVHVTDLTHRPQILIPGALDPDHSKNLTCSVPWACEQGTPPIFSWMSAAPTSLGLR  209

Query  191   TTHSSVLIITPRPQDHGTNLTCQVKFAGAGVTTERTIQLNVTYVPQNPTTGIFPGDGSGK  250
             TTHSSVLIITPRPQDHGTNLTCQVKF GAGVTTERTIQLNV+Y  QNP T IF GDGSGK
Sbjct  210   TTHSSVLIITPRPQDHGTNLTCQVKFPGAGVTTERTIQLNVSYASQNPRTDIFLGDGSGK  269

Query  251   QETRAGVVHGAIGGAGVTALLALCLCLIFFIVKTHRRKAARTAVGRNDTHPTTGSASPKH  310
             Q    GVV GAIGGAGVT LLALCLCLIFF VKTHRRKAARTAVGR DTHP TG  S KH
Sbjct  270   Q----GVVQGAIGGAGVTVLLALCLCLIFFTVKTHRRKAARTAVGRIDTHPATGPTSSKH  325

Query  311   QKKSKLHGPTETSSCSGAAPTVEMDEELHYASLNFHGMNPSKDTSTEYSEVRTQ  (SEQ ID NO:598)
             QKKSKLHG TETS CSG   TVEMDEELHYASLNFHGMNPS+DTSTEYSEVRTQ
Sbjct  326   QKKSKLHGATETSGCSGTTLTVEMDEELHYASLNFHGMNPSEDTSTEYSEVRTQ  (SEQ ID NO:599)
```

FIG. 2



FIG. 3A



FIG. 3B



FIG. 3C



FIG. 3D



FIG. 3E



FIG. 3F



FIG. 3G



FIG. 3H



FIG. 3I



FIG. 3J



FIG. 3K



FIG. 4A



FIG. 4B



FIG. 4C



FIG. 4D



FIG. 4E



FIG. 4F



FIG. 4G



FIG. 4H



FIG. 5A



FIG. 5B



FIG. 5C



FIG. 5D



FIG. 5E



FIG. 5F

FIG. 5G



FIG. 5H



FIG. 5I



FIG. 5J



FIG. 5K



FIG. 5L



FIG. 5M



FIG. 5N



FIG. 5O



FIG. 5P



FIG. 5Q



FIG. 5R



FIG. 5S



FIG. 5T



FIG. 6A



FIG. 6B



FIG. 6C



FIG. 6D



FIG.7A



FIG. 7B



FIG. 7C



FIG. 7D


6000
4000
2000
0
MFI
ADI-11835
ADI-11776
ADI-10159
ADI-11807
ADI-11801
ADI-11815
Lintuzumab
unstained
isotype

FIG. 8


100
80
60
40
20
0
% Internalization
ADI-11835
ADI-11776
ADI-10159
ADI-11807
ADI-11801
ADI-11815
Lintuzumab
isotype
unstained

FIG. 9



FIG. 10A



FIG. 10B


150
100
50
0
FOB
0.1
1
10
100
[X], nM
A40.G59
A40.H76
A40.I07
A40.I35
A44.G59
A44.H76
A44.I07
A44.I35
A49.G59
A49.H76
A49.I07
A49.I35
C26.G59
C26.H76
C26.I07
C26.I35
F47.G59
F47.H76
F47.I07
F47.I35

FIG. 11


% INFγ+/CD107a+ NK cells
50
40
30
20
10
0
C26.H76
A40.H76
F47.H76
A49.H76
A44.H76
C26.G59
A40.G59
F47.G59
A49.G59
A44.G59
C26.I35
A40.I35
F47.I35
A49.I35
A44.I35
C26.I07
A40.I07
F47.I07
A49.I07
A44.I07
H76 mAb
I35 mAb
I07 mAb
G59 mAb
Isotype
E+T
NK only

FIG. 12


% Specific lysis
40
30
20
10
0
C26.H76
A40.H76
F47.H76
A49.H76
A44.H76
C26.G59
A40.G59
F47.G59
A49.G59
A44.G59
C26.I35
A40.I35
F47.I35
A49.I35
A44.I35
C26.I07
A40.I07
F47.I07
A49.I07
A44.I07
E+T

FIG. 13


% Specific lysis
80
60
40
20
0
C26.H76
A40.H76
F47.H76
A49.H76
A44.H76
C26.G59
A40.G59
F47.G59
A49.G59
A44.G59
C26.I35
A40.I35
F47.I35
A49.I35
A44.I35
C26.I07
A40.I07
F47.I07
A49.I07
A44.I07
E+T

FIG. 14



FIG. 15A



FIG. 15B


100
80
60
40
20
0
% Specific lysis
0.01
0.1
1
10
100
[X], nM
A49.I07
A49.I35
A49.H76

FIG. 16



FIG. 17A



FIG. 17B



FIG. 18



FIG. 19



FIG. 20



FIG. 21



FIG. 22



FIG. 23



FIG. 24



FIG. 25



FIG. 26



FIG. 27



FIG. 28



FIG. 29



FIG. 30A



FIG. 30B



FIG. 31



FIG. 32



FIG. 33



FIG. 34


EL4-hNKG2D
FOB
40
30
20
10
0
0.1
1
10
100
1000
10000
100000
Concentration, ng/mL
A49 - F3'-TriNKET-I07
I07-F405L mAb

FIG. 35



FIG. 36A



FIG. 36B



FIG. 37A



FIG. 37B



FIG. 38A



FIG. 38B



FIG. 38C



FIG. 38D



FIG. 39A



FIG. 39B



FIG. 39C



FIG. 40A



FIG. 40B



FIG. 41A



FIG. 41B



FIG. 41C



FIG. 41D



FIG. 41E



FIG. 42A



FIG. 42B



FIG. 43A



FIG. 43B



FIG. 44